Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam
March 09 2021 - 9:00AM
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage
biotechnology company developing product candidates for Alzheimer’s
disease, today announced it has entered into a drug supply
agreement with Evonik Industries AG for simufilam. Under the
agreement, Evonik will supply Cassava Sciences with large-scale,
clinical-grade quantities of simufilam, a drug candidate for the
treatment of Alzheimer’s disease.
“I am pleased with our success to date in being
an effective collaborator with Evonik, a company with a long,
successful and reliable track record of supporting pharmaceutical
supply chains,” said Remi Barbier, President and CEO of Cassava
Sciences.
“We are delighted to be collaborating with
Cassava and contributing to fight Alzheimer’s together. We are
committed to supporting Cassava in their goals to maintain the
quality of life for millions of patients around the world and to
further advance potential treatment options,” says Dr Thomas
Riermeier, head of Evonik’s Health Care business line. Evonik is
one of the world’s largest contract development and manufacturing
organizations (CDMO) for active pharmaceutical ingredients and
advanced intermediates.
About Evonik Evonik is one of
the world leaders in specialty chemicals. The company is active in
more than 100 countries around the world and generated sales of
€12.2 billion and an operating profit (adjusted EBITDA) of €1.91
billion in 2020. Evonik goes far beyond chemistry to create
innovative, profitable and sustainable solutions for customers.
More than 33,000 employees work together for a common purpose: We
want to improve life today and tomorrow.
About Cassava Sciences,
Inc.Cassava Sciences’ mission is to discover and develop
innovations for chronic, neurodegenerative conditions. Over the
past 10 years, Cassava Sciences has combined state-of-the-art
technology with new insights in neurobiology to develop novel
solutions for Alzheimer’s disease. For more information, please
visit: https://www.CassavaSciences.com.
For More Information
Contact:Eric Schoen, Chief Financial
Officereschoen@CassavaSciences.com(512) 501-2450
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Apr 2023 to Apr 2024